

Review

Recent advances in osteoclast biology and pathological bone resorption

H.C. Blair¹ and N.A. Athanasou²

¹Departments of Pathology and Cell Biology and Physiology, University of Pittsburgh School of Medicine and Veteran's Affairs Medical Center, Pittsburgh, USA and ²Nuffield Department of Orthopaedic Surgery, University of Oxford, Nuffield Orthopaedic Centre, Headington, Oxford, England

Summary. The osteoclast is a bone-degrading polykaryon. Recent studies have clarified the differentiation of this cell and the biochemical mechanisms it uses to resorb bone. The osteoclast derives from a monocyte/macrophage precursor. Osteoclast formation requires permissive concentrations of M-CSF and is driven by contact with mesenchymal cells in bone that bear the TNF-family ligand RANKL. Osteoclast precursors express RANK, and the interaction between RANKL and RANK (which is inhibited by OPG) is the major determinant of osteoclast formation. Hormones, such as PTH/PTHrP, glucocorticoids and 1,25(OH)₂D₃, and humoral factors, including TNF α , interleukin-1, TGF β and prostaglandins, influence osteoclast formation by altering expression of these molecular factors. TNF α , IL-6 and IL-11 have also been shown to promote osteoclast formation by RANKL-independent processes. RANKL-dependent/independent osteoclast formation is likely to play an important role in conditions where there is pathological bone resorption such as inflammatory arthritis and malignant bone resorption. Osteoclast functional defects cause sclerotic bone disorders, many of which have recently been identified as specific genetic defects. Osteoclasts express specialized proteins including a vacuolar-type H⁺-ATPase that drives HCl secretion for dissolution of bone mineral. One v-ATPase component, the 116 kD V₀ subunit, has several isoforms. Only one isoform, TCIRG1, is up-regulated in osteoclasts. Defects in TCIRG1 are common causes of osteopetrosis. HCl secretion is dependent on chloride channels; a chloride channel homologue, CLCN7, is another common defect in osteopetrosis. Humans who are deficient in carbonic anhydrase II or who have defects in phagocytosis also have variable defects in bone remodelling. Organic bone matrix is degraded by thiol proteinases, principally

cathepsin K, and abnormalities in cathepsin K cause another sclerotic bone disorder, pycnodysostosis. Thus, bone turnover in normal subjects depends on relative expression of key cytokines, and defects in osteoclastic turnover usually reflect defects in specific ion transporters or enzymes that play essential roles in bone degradation.

Key words: CLIC5, Vitamin D, M-CSF, CAII

Introduction

Bone resorption occurs continuously throughout life to maintain skeletal mass and calcium balance. This involves coupled bone formation and resorption, which are carried out by osteoblasts and osteoclasts respectively. The osteoclast is a multinucleated cell specialised to carry out lacunar resorption (Fig. 1). Osteoclasts are not commonly seen in normal adult bone but are often found at sites of osteolysis in diseases affecting bones and joints. Cellular and hormonal/humoral factors which influence the extent of pathological bone resorption act by regulating the activity and number (i.e. formation and survival) of osteoclasts.

Osteoclast origin and cell lineage

It is now well-established that osteoclasts are of haematopoietic rather than mesenchymal bone stromal cell origin. Evidence to support this conclusion was initially provided by experiments employing parabiosis or marrow transplants (Walker, 1973, 1975). Further studies showed that osteoclast precursors are derived from the pluripotential haematopoietic stem cell from which other leucocytes are derived and that the osteoclast lineage shares marrow precursors with monocytes and macrophages, including committed precursors (CFU-GM) for cells of this lineage (Kurihara et al., 1990; Alvarez et al., 1991). More recently,

transgenic and stem cell differentiation studies have provided unequivocal evidence as to the haematopoietic nature of osteoclasts, and conversely have shown that the chondrocytes and osteoblasts arise from mesenchymal stem cells (Tondravi et al., 1997; Pittenger et al., 1999). The human mononuclear osteoclast precursor circulates in the monocyte fraction of peripheral blood. It expresses the monocyte/macrophage integrins CD11b-c and the lipopolysaccharide receptor antigen CD14 (Athanasou and Quinn, 1990; Fujikawa et al., 1996), and is entirely negative for phenotypic markers of the mature osteoclast, such as tartrate-resistant acid phosphatase (TRAP), vitronectin receptor (VNR, the $\alpha_v \beta_3$ integrin), calcitonin receptors and bone resorption (Ross et al., 1993, Roux et al., 1997). Although these precursors do not represent a distinct subpopulation in terms of expression of mononuclear phagocyte markers, only a minority of circulating mononuclear cells (approximately 2-5%) within the human monocyte fraction appear to be capable of osteoclast differentiation (Fujikawa et al., 1996). Rapid and dramatic changes in the phenotype of these mononuclear precursor cells occur in the process of osteoclast differentiation; this involves stepwise loss and acquisition of specific phenotypic markers for macrophages and osteoclast respectively (Takahashi et al., 1994; Faust et al., 1999).

Identification of molecular factors mediating osteoclast differentiation

In vitro systems of osteoclast formation from marrow and circulating mononuclear precursors




Fig. 1. Osteoclasts in medullary trabecular bone. This section, showing abundant osteoclasts in a calcium-starved laying hen, is stained with hematoxylin to show cells and nuclei (blue), and is labelled with antibody to the vacuolar H⁺-ATPase (brown) which is expressed prominently at the osteoclast-bone interface (asterisks) (Blair et al., 1989). Osteoclasts are multinucleated (arrowheads). This is a frozen section; osteoclasts are degradative cells with abundant proteinases; in bone fixed by conventional means osteoclasts are often autolysed. The field shown is 125 μ m wide and was photographed using 40x objective lens.

established the necessity for the presence of macrophage-colony stimulating factor (M-CSF) and contact with an osteoblast/bone stromal cell population (Jimi et al., 1996). M-CSF, which is produced at varying levels by many mesenchymal cells including osteoblasts, is an absolute requirement for the proliferation and differentiation of osteoclast progenitors (Tanaka et al., 1993). M-CSF acts through c-fms, the M-CSF receptor, which has been demonstrated to be essential for normal osteoclast differentiation (Yoshida et al., 1990). Fms is a transmembrane tyrosine kinase-receptor; it belongs to a large superfamily that includes the insulin receptor. Fms is an integral membrane component in monocyte/macrophage family cells. Its second messengers include the intracellular tyrosine kinase src, which is also required for normal osteoclast differentiation (Soriano et al., 1991). As direct cell-cell interaction between mononuclear phagocyte progenitors and bone stromal cells appeared to be essential for osteoclastogenesis *in vitro* (Fujikawa et al., 1996; Jimi et al., 1996), it was postulated that a membrane-associated factor on bone stromal cells is essential for osteoclast differentiation. Direct attempts to isolate this osteoclast activating factor produced many candidate cytokines but were unsuccessful. However, a protein that did the reverse, blocking osteoclast development *in vitro* and *in vivo*, was discovered by two groups in 1997. This osteoclastogenesis inhibitory factor, osteoprotegerin (OPG) turned out to be a new dimeric ~50 kD tumour necrosis factor (TNF) decoy receptor (Simonet et al., 1997; Tsuda et al., 1997; Yasuda et al., 1998). Several such secreted TNF-binding proteins are known (the decoy receptors DcR1/TRID, DcR2/TRUNDD and DcR3, as well as soluble alternative transcripts of Fas and DR3/TNFRSF25). OPG-deficient mice exhibit osteoporosis; transgenic mice overexpressing OPG develop osteopetrosis (Simonet et al., 1997; Mizuno et al., 1998; Lacey et al., 1998). Expression cloning to find the proteins that bind OPG identified a previously characterized TNF-family protein, TRANCE (TNF-related activation-inducing cytokine), which had been shown to activate the TNF-family receptor RANK (receptor activator of nuclear factor- κ B) a T-lymphocyte product which is a survival factor for dendritic cells (Anderson et al., 1997; Wong et al., 1997). This TNF-family ligand is now generally named after its receptor, RANK-ligand or RANKL.

RANKL exists in cell membrane-bound and soluble forms but is mainly a membrane-bound protein *in vivo* (Hofbauer et al., 2000). As with any TNF, however, its receptor-binding domain alone is active. TNFs generally function as trimers or larger complexes, which cause the association in the target membrane of multiple activated receptor subunits. In the presence of M-CSF, RANKL induces osteoclast formation from spleen cells and monocyte/macrophage cell populations in the absence of bone stromal cells (Kong et al., 1999). This generally requires serum-containing medium and can be finicky, varying between cell preparations and serum lots; this

has led many investigators to believe that additional uncharacterized growth factors or cell-cell interactions may be involved in this process. Nevertheless, RANKL knockout mice exhibit osteopetrosis and defects in tooth eruption that are associated with an absence/deficiency of osteoclasts (Kong et al., 1996). These findings indicate that RANKL is a key stromal cell factor required for osteoclast formation during normal bone turnover in mice.

RANKL mRNA is most abundant in skeletal tissues and lymphoid tissues that are active in mediating an immune response (e.g. lymph node, thymus, spleen, Peyer's patches) (Kong et al., 1996). RANKL is expressed by hypertrophic chondrocytes and RANKL expression is most abundant in the growth plate and the metaphyseal periosteum in adult mouse bone (Akiyama et al., 1999; Kartsogiannis et al., 1999). RANKL is also expressed by endothelial cells and some fibroblasts and it is found at lower levels in other tissues such as heart, skeletal muscle, and lung (Kartsogiannis et al., 1999). Animals injected with RANKL only form osteoclasts in bone and not in other tissues. This observation indicates that there are other specific factors present in the bone microenvironment which are required for the differentiation of osteoclasts from precursor cells.

In contrast to RANKL, OPG is expressed in high concentrations in a variety of tissues including endothelial cells, fibroblasts, smooth muscle cells, monocyte, dendritic cells, B lymphocytes and cancer cells (Kartsogiannis et al., 1999). OPG is mainly produced by cells of the osteoblast lineage in bone. It inhibits the differentiation, survival and fusion of osteoclast precursors, induces osteoclast apoptosis and inhibits mature osteoclast activity. Decoy receptors such as OPG typically have relatively broad binding specificity, and OPG is known to bind at least one other TNF-family protein, the TNF-related apoptosis inducing ligand (TRAIL) (Emery et al., 1998).

RANKL-RANK signalling

RANKL, via its receptor RANK, activates nuclear factor- κ B (NF- κ B). Activation of NF- κ B is not a unique property of RANK. It is shared by a number of other receptors including those of TNF. Further, RANK activates other intermediate signals including TNF-receptor-associated factors (TRAFs), 2, 5 and 6 (Kim et al., 1999; Wong et al., 1999). TRAFs are signalling molecules that act as second messengers to a variety of IL-1/Toll receptors as well as the TNF family (Chung et al., 2002). TRAFs 2,5, and 6 are not specific to RANK. TRAF 6 is a key IL-1 intermediate signal. From these pathways, a basis for reinforcement of RANKL signalling or alternative osteoclast differentiation entirely by other TNFs and IL-1 can be inferred, and indeed this idea is supported by recent studies (vide infra). Additional regulatory pathways activated by RANK include the c-Jun N-terminal kinase (Kim et al., 1999), which is downstream of a variety of cytokines,

and src (Wong et al., 1999), which mediates signals of tyrosine kinase receptors.

The NF- κ B signal also interacts with DNA-transcription-cofactor Smad proteins (Lopez-Rovira et al., 2000). These interactions may be important in the co-operative effect of 1,25 dihydroxyvitamin D-3 [1,25(OH)₂D₃] and transforming growth factor β (TGF β) in osteoclast differentiation (Yanagisawa et al., 1999). Smad genes were identified as homologues of the *Drosophila* mad (mothers against decapentaplegic) and *Caenorhabditis elegans* sma genes (Liu et al., 1996). Smads regulate a variety of transcription factors and only some of them (R-Smads) interact with receptors, of which two principal subtypes mediate effects of TGF β -superfamilies in the broad classes of TGFs/activins (AR-Smads 2 and 3) and BMPs/GDFs (BR-Smads 1, 5, and 8) (Miyazono et al., 2001). Smad activity is regulated by kinases, including the serine/threonine kinase activity of the TGF β -superfamily type I and II receptors themselves. Smad3, an AR-smad, is a cofactor for the vitamin D receptor (Yanagisawa et al., 1999), TGF β (Yanagisawa et al., 1999), and NF- κ B (Lopez-Rovira et al., 2000).

The core NF- κ B signalling pathway has been extensively studied. In the cytoplasm, NF- κ B is present as an inactive complex with inhibitor κ B (I κ B). IL-1, TNF α and RANK activate kinases that phosphorylate I κ B, leading to ubiquitin-related degradation of the inhibitory complex which allows nuclear localization of NF- κ B (Mercurio and Manning, 1999). Acting via TRAF-6, IL-1 activates pathways replacing the late stages of RANK signalling (Lomag et al., 1999). The TRAF pathways are also activated by TNF α (Kobayashi et al., 2000). This convergence on NF- κ B emphasizes its role in osteoclast differentiation. There are two forms of NF- κ B that have redundant functions. When both are eliminated, a defect in osteoclast differentiation and osteopetrosis occurs (Iotsova et al., 1997).

Regulation of RANKL-induced osteoclast formation by calciotropic hormones and cytokines

Experiments *in vitro*, using a variety of culture systems, have shown that osteoblast and bone stromal cell RANKL expression is up-regulated, and OPG expression downregulated by calciotropic hormones and bone cytokines that stimulate bone degradation, including PTH, 1,25(OH)₂D₃, glucocorticoids, IL-1, IL-11, TNF α and prostaglandin-E₂ (Hofbauer et al., 1999; Kitazawa et al., 1999; Nakashima et al., 2000; Chung et al., 2001; Horwood et al., 2001; Koseki et al., 2002; Li et al., 2002). Some growth factors that affect monocyte-lineage cells as well as mesenchymal cells, such as TGF β , down-regulate RANKL expression in osteoblasts (Quinnet et al., 2001), but increase osteoclast differentiation in cultures of haematopoietic cells incubated with RANKL and M-CSF (Koseki et al., 2002); this may in part be due to TGF β stimulation of osteoblast OPG expression and pre-osteoclast RANK

expression (Thirunavukkarasu et al., 2001). Stimuli that promote osteoclast formation typically decrease OPG expression in osteoblast lineage cells (Murakami et al., 1998). Estradiol is an important case where many complex observations have been reported and a consistent mechanism is not clear; for a summary see (Cao et al., 2003). Consensus *in vitro* observations on RANKL/OPG and some *in vivo* correlative data on osteoclast formation and activity are summarized in Table 1.

The cytokines other than RANKL that affect osteoclast differentiation are probably of importance in pathological conditions where large amounts of these factors are produced. IL-1, IL-6 and TNF α can be made by macrophages as well as mesenchymal cells with a variety of stimuli. They are produced by mesenchymal cells in postmenopausal osteoporosis (Marie et al., 1993), and by synovial fibroblasts and macrophages in rheumatoid arthritis (Ridderstad et al., 1991). IL-1 and IL-6 are coordinated with RANKL or TNF α expression in stromal cells (Atkins et al., 2000), and are stimulated by PTH (Onyia et al., 1997). IL-1, IL-6 and TNF α may be autocrine or paracrine stimuli (Tani-Ishii et al., 1999), and their signals are also regulated by secondary factors. IL-6 induces osteoclast differentiation via gp130 (Suda et al., 1995). The IL-1 decoy receptor, IL-1RII, can limit expression of pro-apoptotic TNF family proteins by monocyte family cells that are involved in arthritic destruction of joints (Bessis et al., 2000). Other important cytokines in inflammation and repair include TGF β and prostaglandin E $_2$. TGF β is typically identified with macrophages and is prominent in inflammatory

tissues (Cutolo et al., 1993), and prostaglandin E $_2$ appears to be produced by osteoblasts and to play a major role in the repair of bone (Zhang et al., 2002). There has been considerable interest recently in T-cell cytokines such as IL-7 and IL-17 (Lubbets et al., 2003; Toraldo et al., 2003), although the role of T-cells in bone loss is still not well characterized.

Aside from the RANKL pathway, the M-CSF/fms receptor pathway also has alternative stimuli. At least two tyrosine kinase receptors related to Fms are expressed in bone. Met and Kit are tyrosine kinase receptors related to Fms, which are expressed in osteoclasts and precursors (Gattei et al., 1996; Grano et al., 1996). The ligands for these receptors, scf and hgf, are expressed by osteoblasts, (Grano et al., 1996; Blair et al., 1999). Their physiological functions are uncertain. However, the intracellular signals stimulated by Met, Kit, and Fms have prominent common effects mediated by src and cbl, suggesting that Met and Kit may modify or augment the osteoclast-differentiation function of Fms under some circumstances.

RANKL-induced osteoclast formation and the role of cytokines in pathological bone resorption

Although it is probable that changes in RANKL expression or RANK signalling occur in clinical bone diseases characterised by pathological bone resorption, it should be noted that as yet such links are theoretical and not proven. Despite the transgenic mouse data on osteopetrosis and RANKL, there have not been clinical reports linking RANKL defects to osteopetrosis.

Table 1. Regulation of expression of RANKL relative to OPG by hormones and cytokines. Osteoblasts and mesenchymal cells are major RANKL-expressing cells in normal bone turnover. In rheumatoid arthritis, the lymphoid inflammatory infiltrate may also be a major producer of osteoclast-inducing RANKL. For brevity, references list only first author and year; see references for complete authors.

CYTOKINE OR HORMONE	RATIO OF RANKL TO OPG	COMMENT	KEY REFERENCE
1,25(OH) $_2$ D $_3$	Increase	In vivo results correlate poorly	Koseki, 2002; Horwood, 2001; Kitazawa, 1999; Murakami, 1998; Suda 2003
Estradiol	Variable	Sex and receptor dependent; also affects RANK signalling	Cao 2003, Saika 2001, Lindberg 2001, Srivasta 2001
Glucocorticoids	Increase		Kitazawa 1999; Chung, 2001;
PTH	Increase		Koseki et al., 2002; Horwood, 2001; Murakami, 1998;
IL-1	Increase		Nakaxhima, 2000; Hofbauer, 1999; Murakami, 1998
IL-6	None	Affects osteoclast formation via macrophage receptors	Nakaxhima, 2000; Hofbauer, 1999
L-7	Increase	Increases RANKL in T-cells	Toraldo, 2003
IL-11	Increase		Horwood, 2001; Nakaxhima 2000
IL-17	Increase	T-cell derived cytokine active in induced murine arthritis	Lubbets, 2003
PGE $_2$	Increase		Koseki et al., 2002, Li, 2002; Murakami, 1998
TGF β	Decrease	In macrophages, stimulates osteoclast formation	Koseki et al., 2002, Quinn 2001; Thirunavukkarasu, 2001
TNF α	Increase	Affects macrophage response as well as osteoblasts	Nakaxhima, 2000; Hofbauer 1999

Osteoclast pathology

RANKL polymorphisms have not been identified in Paget's disease (Wuyts et al., 2001), but mutations in the RANK and OPG genes have been noted in familial expansile osteolysis and hyperostosis corticalis deformans juvenilis ("juvenile Paget's disease") (Hughes et al., 2000; Whyte et al., 2002). One possibility is that in humans, the RANK system is so critical that only mild defects, which may not be characterized for some time, are survivable.

Changes in OPG, which is a circulating decoy receptor that regulates the activity of TNF family proteins, have been implicated in bone disease. Glucocorticoid therapy reduces circulating OPG (Sasaki et al., 2001) and may contribute to secondary osteoporosis in this way. OPG may be important in the physiological response to bone loss, since the level of OPG is increased in postmenopausal women (Yano et al., 1999). Recombinant OPG has been proposed as a therapeutic agent for osteoporosis and related disorders, but its utility is still under study. There is also interest in OPG polymorphisms as possible causes of sporadic osteoporosis and other disorders (Langdahl et al., 2002).

Bone loss in arthritis appears to be related to TNF α expression, and TNF α has been implicated in alternative mechanisms of osteoclast differentiation (Kudo et al., 2002). This topic is of some importance as it has been shown that TNF α -blocking therapy produces sustained improvement in rheumatoid arthritis (Taylor, 2003). There is also interest in the effect of OPG on bone loss in arthritis. OPG deficiency appears to be important in the progress of TNF α -mediated arthritis (Haynes et al., 2003). OPG directly ameliorates osteoclastic activity in animal models of arthritis, although the mechanism involved is unclear (Redlich et al., 2002; Romas et al., 2002). A direct clinical relationship linking TNF α

therapy to normalization of serum OPG and RANK, however, has not been shown (Ziolkowska et al., 2002). Further, TNF α directly up-regulates OPG in human mesenchymal stem cells (Brandstrom et al., 2001), suggesting that TNF α effects on osteoclast formation are not due solely to RANKL activity. Elevated OPG has also been demonstrated in human rheumatoid arthritis (Feuerherm et al., 2001). These findings argue that TNF α -mediated augmentation of bone degradation may be important in vivo.

Although pro-inflammatory cytokines influence osteoclast formation by modulating RANKL and OPG expression on osteoblasts and other cells, as discussed above, these cytokines also induce osteoclast formation by a RANKL-independent mechanism (Kudo et al., 2002, 2003; Sabokbar et al., 2003). Mouse marrow cultures and cultures of human monocytes incubated with TNF α induce osteoclast differentiation from mononuclear precursors; the addition of IL-1 markedly stimulates the resorption of the osteoclasts which are formed in this way (Kobayashi et al., 2000; Kudo et al., 2002). In man, this RANKL-independent mechanism results in the formation of numerous small osteoclasts that produce relatively small resorption pits (Kudo et al., 2002); this process of osteoclast formation is thus quantitatively and qualitatively distinct from RANKL-dependent osteoclast formation where large resorption pits are produced (Fig. 2). IL-6 and IL-11 have also been shown to promote human osteoclast formation in a similar manner (Kudo et al., 2003).

It has been reported that TNF α stimulates osteoclast differentiation from macrophages only in rodent cell cultures in which there are permissive concentrations of RANKL (Lam et al., 2000) and, on this basis, it has been suggested that TNF α alone does not induce osteoclast formation. There is disagreement as to whether basal levels of RANKL are required for osteoclast formation in all species. RANK-deficient mice fail to make a significant number of osteoclasts, arguing for an essential role for RANK signalling in normal bone modelling (Dougall et al., 1999). However, these animals also cannot form lymph nodes, and it is unclear how other cytokine signalling processes are affected. Further, RANK and RANKL deficient mice, though osteopetrotic, are viable, so minor bone degradation may occur in mice without RANK signalling. OPG abolishes bone resorption in TNF-mediated arthritis (Redlich et al., 2002), but OPG is not absolutely specific for RANKL, so this could reflect effects on other TNF-family proteins.

The current findings suggest that there are two pathways of osteoclast formation, one RANKL-induced, the other either completely or mainly RANKL-independent and cytokine-induced. These pathways may operate under different tissue conditions and are not mutually exclusive (Fig. 3). Whether the alternative RANKL-independent mechanism operates with cells 'primed' by minimal RANKL signals is probably not functionally important. Rather, what is important, is the




Fig. 2. Lacunar resorption by osteoclasts made with RANKL and M-CSF (A) and TNF α and M-CSF (B). The resorption pits produced by cells cultured with TNF α are notably smaller than those produced by cells which differentiate in the presence of RANKL. Each photograph is ~200 μ m wide and was photographed using a 10x objective lens.




Fig. 3. Alternative pathways for osteoclast terminal differentiation. **A.** In normal bone turnover the macrophage-family signal M-CSF and the tumor necrosis factor-family signal RANKL are central to osteoclast formation, and the major sources are cell-surface presented growth and differentiation factors from mesenchymal cells including osteoblasts. However, circulating signals including 1,25 dihydroxyvitamin D3 and other factors not currently defined may be required, and this process is regulated by secondary hormones and cytokines (Table 1). **B.** In inflammatory and reparative situations, as in this osteoblast-denuded/ necrotic bone surface, normal sources of RANKL and M-CSF may be limited and secondary factors that stimulate the same pathways are of increased importance. These may include soluble growth factors produced by macrophages such as the tumor necrosis factor-family signal TNF α , transforming growth factor- β , and interleukins 1 and 6; for clarity only some highly expressed cytokines are shown (see Table 1). RANKL is produced by T-lymphocytes that are present in inflammatory bone disease, so this signal may be present, albeit at reduced levels. However, in vitro osteoclast production can be accomplished without RANKL from CD 14 human blood monocytes.




Fig. 4. Major biochemical and transport pathways in the osteoclast. The driving force is a vacuolar-type H⁺-ATPase; this is electrically coupled to chloride transport. Chloride-bicarbonate exchange maintains intracellular pH neutrality. Other important features include a tight bone attachment, which is not well characterized but is known to depend on the vitronectin receptor, acid proteinase expression, and vacuolar transcytosis for removal of degraded bone products.

role of additional cytokines including TNF α in the local bone degradation in diseases such as rheumatoid arthritis. At sites of physiological (e.g. normal bone turnover) or pathological (e.g. osteoporosis) bone

resorption, where few or no inflammatory cells are present and levels of inflammatory and reparative cytokines (Table 1) are low, RANKL-induced osteoclast formation would predominate. However, in inflammatory diseases of bone and joint, where numerous inflammatory cells and abundant cytokines are present, RANKL-independent osteoclast formation may predominate. It is interesting to note that glucocorticoids have opposing effects on these two mechanisms, promoting RANKL-induced but inhibiting TNF-induced osteoclast formation (Kudo et al., 2002). This is in keeping with the fact that systemic glucocorticoids induce osteoporosis yet control osteolysis that occurs secondary to inflammatory diseases such as rheumatoid arthritis (Neeck et al., 2002).

Osteoclast physiology and developmental defects

The basic mechanisms that mediate the removal of bone mineral by the osteoclast were defined by the 1990s (Fig. 4). However, the detailed structure of specific transport proteins is still an area of active investigation, and, as the mechanisms have been refined, this understanding has been of increasing practical value. An essential feature that differentiates the osteoclast from other macrophage polykaryons (giant cells) is massive expression of a cell-surface, vacuolar-like H⁺-ATPase (Blair et al., 1989), which is required for the

Osteoclast pathology

energy-consuming step of the acid secretion that dissolves bone mineral. The protons derive indirectly from CO_2 in a process accelerated by carbonic anhydrase type II, absence of which leads to a type of osteopetrosis with variable severity and correlated renal and mental problems (Hunter et al., 1991; Alper, 2002). The v- H^+ -ATPase is electrogenic so it must have an electrical balance, which is a Cl^- channel (Blair and Schlesinger, 1990; Blair et al., 1991), producing HCl. Cellular acid-base balance is maintained by a $\text{Cl}^-/\text{HCO}_3^-$ exchanger on the basolateral cell membrane (Teti et al., 1989). Osteoclasts secrete an acidic collagenase, cathepsin K, and a phosphatase active in acidic environments (tartrate-resistant acid phosphatase, or TRAP), which are required for efficient bone degradation under laboratory conditions (Tezuka et al., 1994; Hollberg et al., 2002). To date, TRAP is useful mainly as an osteoclast marker and deficiencies created in laboratory animals have no correlates in human disease (Hollberg et al., 2002). On the other hand, deficiency of cathepsin K is responsible for a sclerotic bone disorder, pycnodysostosis, also called Toulouse-Lautrec syndrome (Gelb et al., 1996). The osteoclast forms a tightly sealed bone attachment compartment that allows the extracellular acidification. This sealing process depends on the vitronectin receptor, the $\alpha\text{v}\beta 3$ integrin (Ross et al., 1993). Degraded calcium and collagen fragments are transported through the osteoclast by vacuolar transcytosis (Nesbitt and Horton, 1997; Salo et al., 1997).

Recently, important discoveries have been made in osteoclastic membrane transporter isotypes. The v-type H^+ -ATPase is composed of membrane (V_0) and cytoplasmic (V_1) subassemblies; the V_0 comprises a 17 kDa hydrogen channel and a 116 kD protein with several transmembrane passes. The V_1 assembly is a nanomotor with rotation coupled to ATP hydrolysis and acid transport. The membrane anchoring V_0 subunit, particularly its 116 kD component, appear to be crucial for membrane insertion and the elevated H^+ -ATPase expression in the osteoclast. Four isoforms of the 116 kD V_0 component are known, with the third variant, TCIRG1 (A3) the (only) one whose expression is amplified in the osteoclast (Li et al., 1999). Thus, defects in this protein would be expected to be associated with osteoclastic acid pumping defects, and this has proved not only to be correct but to be a surprisingly common cause of osteopetrosis (Frattoni et al., 2000; Michigami et al., 2002), as well as a possible cause of variability in bone density (Carn et al., 2002). Another acid secreting cell related to skeletal metabolism, the renal intercalated cell, also has a unique 116 kD V_0 subunit, the fourth described, which is required for expression and insertion of the v-ATPase in this cell (Smith et al., 2000, 2001).

A 62 kDa Cl^- channel isolated from avian osteoclast ruffled border by affinity to the stilbene anion channel inhibitor DIDS was reconstituted chloride transport in planar lipid bilayers, and was characterized as a rectifying channel with 16.7 pS conductivity (Alper,

2002). This channel, called Clor.62 (Schlesinger et al., 1997), has SH2 and SH3 domains and co-precipitates src. Src antisense and Clor.62 antisense reduced the activity of acid secretion and degradation of bone, so this channel is thought to carry the bulk of the chloride current balancing the H^+ -ATPase. There is, however, no correlation to human disease. The human homologue is intracellular chloride channel 5 (CLIC5), one of a group of chloride channels typically expressed intracellularly and believed to function in capacities such as acid secretion, but which as yet are poorly characterized. Transgenic animals and other molecular methods may be useful in characterizing the role of this transporter in future, but have not been reported to date. On the other hand, transgenic mice deficient in a chloride channel analogue, CLC-7 (Brandt and Jentsch, 1995; Kornak et al., 1999), have osteopetrosis (Cleiren et al., 2001; Kornak et al., 2001). Defects in CLC7 are associated with osteopetrosis in several families. Most defects in CLC7 appear to be silent unless homozygous. While CLC7 expression is essential, lack of channel activity in *Xenopus* (Brandt and Jentsch, 1995), except possibly at low pH that also activates endogenous *Xenopus* chloride channels (Diewald et al., 2002), suggest the possibility that this is a regulatory membrane protein rather than the actual chloride conductance, which the avian osteoclast work suggests is a member of the CLIC family, possibly CLIC5.

There are multiple additional genetic bases for osteoclastic dysfunction. Transgenic mice deficient in src have osteopetrosis, and signals including cbl downstream of src are important (Tanaka et al., 1996), although clear clinical correlates are not available, possibly because defects in these central tyrosine-kinase pathways are embryonic-lethals. Free-radical production defects, such as in macrophage and neutrophil activity disorders and chronic granulomatous diseases, often also cause mild osteopetrosis (Yang et al., 1999; Madyastha et al., 2000). This suggests that free-radical production is also important to bone degradation, although the mechanism is unclear. Not all osteoclast defects correlate with any known pathway, though, suggestion that further cell fusion, protein transport or precursor defects, with or without immune disease, probably exist.

One further pathway that deserves mention is that HCl secretion is critical to the function of bone-adsorbed antiresorptive agents. Bisphosphonates are antimetabolites that bind hydroxyapatite, and are almost totally bound to bone mineral under physiological conditions (Carano et al., 1990). Osteoclasts, by dissolving the hydroxyapatite with acid, cause release of the bone-bound antimetabolites, an autoinhibitory process that, because of its relation to the unique osteoclast physiology, has very few side effects.

Acknowledgements. NAA and HLB have been supported by the Nuffield Foundation, the Wellcome Trust (UK), Action Research, Research Into Ageing and by the Department of Veterans' Affairs (USA), and the National Institutes of Health (USA).

References

- Alper S.L. (2002). Genetic diseases of acid-base transporters. *Annu. Rev. Physiol.* 64, 899-923.
- Alvarez J.I., Teitelbaum S.L., Blair H.C., Greenfield E.M., Athanasou N.A. and Ross F.P. (1991). Generation of avian cells with the osteoclast phenotype from mononuclear phagocytes. *Endocrinology* 128, 2324-2335.
- Akiyama H., Shigeno C., Iyama K., Ito H., Hiraki Y., Konishi J. and Nakamura T. (1999). Indian hedgehog in the late-phase differentiation in mouse chondrogenic EC cells, ATDC5: upregulation of type X collagen and osteoprotegerin ligand mRNAs. *Biochem. Biophys. Res. Commun.* 257, 814-820.
- Anderson D.M., Maraskovsky E., Billingsley W.L., Dougall W.C., Tometsko M.E., Roux E.R., Teepe M.C., DuBose R.F., Cosman D. and Galibert L. (1997). A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. *Nature* 390, 175-179.
- Athanasou N.A. and Quinn J. (1990). Immunophenotypic differences between osteoclasts and macrophage polykaryons: immunohistological distinction and implications for osteoclast ontogeny and function. *J. Clin. Pathol.* 43, 997-1003.
- Atkins G.J., Haynes D.R., Geary S.M., Loric M., Crotti T.N. and Findlay D. (2000). Coordinated cytokine expression by stromal and hematopoietic cells during human osteoclast formation. *Bone* 26, 653-661.
- Bessis N., Guery L., Mantovani A., Vecchi A., Sims J.E., Fradelizi D. and Boissier M.C. (2000). The type II decoy receptor of IL-1 inhibits murine collagen-induced arthritis. *Eur. J. Immunol.* 30, 867-875.
- Blair H.C., Julian B.A., Cao X., Jordan S.E. and Dong S.S. (1999). Parathyroid hormone-regulated production of c-kit ligand in human osteoblasts and osteoblast-like cells. *Biochem. Biophys. Res. Commun.* 255, 778-784.
- Blair H.C. and Schlesinger P.H. (1990). Purification of a stilbene sensitive chloride channel and reconstitution of chloride conductivity into phospholipid vesicles. *Biochem. Biophys. Res. Commun.* 171, 920-925.
- Blair H.C., Teitelbaum S.L., Ghiselli R. and Gluck S. (1989). Osteoclastic bone resorption by polarized vacuolar proton pump. *Science* 245, 855-857.
- Blair H.C., Teitelbaum S.L., Koziol C.M. and Schlesinger P.H. (1991). Passive chloride permeability charge coupled to the electrogenic H⁺-ATPase of avian osteoclast ruffled membrane. *Am. J. Physiol.* 260, C1315-C1324.
- Brandstrom H., Bjorkman T. and Ljunggren O. (2001). Regulation of osteoprotegerin secretion from primary cultures of human bone marrow stromal cells. *Biochem. Biophys. Res. Commun.* 280, 831-835.
- Brandt S. and Jentsch T.J. (1995). CIC-6 and CIC-7 are two novel broadly expressed members of the CLC chloride channel family. *FEBS Lett.* 377, 15-20.
- Cao L., Bu R., Oaklady J.I., Kalla S.E. and Blair H.C. (2003). Estrogen receptor- β modifies expression of matrix proteins in human MG63 osteosarcoma cells. *J. Cell Biochem.* 89, 152-164.
- Carano A., Teitelbaum S.L., Konsek J.D., Schlesinger P.H. and Blair H.C. (1990). Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. *J. Clin. Invest.* 85, 456-461.
- Carn G., Koller D.L., Peacock M., Hui S.L., Evans W.E., Conneally P.M., Johnston C.C. Jr, Foroud T. and Econs M.J. (2002). Sibling pair linkage and association studies between peak bone mineral density and the gene locus for the osteoclast-specific subunit (OC116) of the vacuolar proton pump on chromosome 11p12-13. *J. Clin. Endocrinol. Metab.* 87, 3819-3824.
- Chung H., Kang Y.S., Hwang C.S., Moon I.K., Yim C.H., Choi K.H., Han K.O., Jang H.C., Yoon H.K. and Han I.K. (2001). Deflazacort increases osteoclast formation in mouse bone marrow culture and the ratio of RANKL/OPG mRNA expression in marrow stromal cells. *J. Korean Med. Sci.* 16, 769-773.
- Chung J.Y., Park Y.C., Ye H. and Wu H. (2002). All TRAFs are not created equal: common and distinct molecular mechanisms of TRAF-mediated signal transduction. *J. Cell Sci.* 115, 679-688.
- Cleiren E. (2001). Albers-Schonberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the CICN7 chloride channel gene. *Hum. Mol. Genet.* 10, 2861-2867.
- Cutolo M., Sulli A., Barone A., Serio B. and Accardo S. (1993). Macrophages, synovial tissue and rheumatoid arthritis. *Clin. Exp. Rheumatol.* 11, 331-339.
- Diewald L., Rupp J., Dreger M., Hucho F., Gillen C. and Nawrath H. (2002). Activation by acidic pH of CLC-7 expressed in oocytes from *Xenopus laevis*. *Biochem. Biophys. Res. Commun.* 291, 421-424.
- Dougall W.C., Glaccum M., Charrier K., Rohrbach K., Brasel K., De Smedt T., Daro E., Smith J., Tometsko M.E., Maliszewski C.R., Armstrong A., Shen V., Bain S., Cosman D., Anderson D., Morrissey P.J., Peschon J.J. and Schuh J. (1999). RANK is essential for osteoclast and lymph node development. *Genes Dev.* 13, 2412-2424.
- Emery J.G., McDonnell P., Burke M.B., Deen K.C., Lyn S., Silverman C., Dul E., Appelbaum E.R., Eichman C., DiPrinzio R., Dodds R.A., James I.E., Rosenberg M., Lee J.C. and Young P.R. (1998). Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. *J. Biol. Chem.* 273, 14363-14367.
- Faust Lacey D.L., Hunt P., Burgess T.L., Scully S., Van G., Eli A., Qian Y. and Shalhoub V. (1999). Osteoclast markers accumulate on cells developing from human peripheral blood mononuclear precursors. *J. Cell Biochem.* 72, 67-80.
- Feuerherm A.J., Borset M., Seidel C., Sundan A., Leistad L., Ostensen M. and Faxvaag A. (2001). Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritis. *Scand. J. Rheumatol.* 30, 229-234.
- Fratini A., Orchard P.J., Sobacchi C., Giliani S., Abinun M., Mattsson J.P., Keeling D.J., Andersson A.K., Wallbrandt P., Zecca L., Notarangelo L.D., Vezzoni P. and Villa A. (2000). Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis. *Nature Genet.* 25, 343-346.
- Fujikawa Y., Quinn J.M., Sabokbar A., McGee J.O. and Athanasou N.A. (1996). The human osteoclast precursor circulates in the monocyte fraction. *Endocrinology* 137, 4058-4060.
- Gattei V., Aldinucci D., Quinn J.M., Degan M., Cozzi M., Perin V., Luliis A.D., Juzbasic S., Improta S., Athanasou N.A., Ashman L.K. and Pinto A. (1996). Human osteoclasts and preosteoclast cells (FLG 29.1) express functional c-kit receptors and interact with osteoblast and stromal cells via membrane bound stem cell factor. *Cell Growth Diff.* 7, 753-763.
- Gelb B.D., Shi G.P., Chapman H.A. and Desnick R.J. (1996). Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. *Science* 273, 1236-1238.

Osteoclast pathology

- Grano M., Galimi F., Zamboni G., Colucci S., Cottone E., Zallone A.Z. and Comoglio P.M. (1996). Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro. *Proc. Nat. Acad. Sci. USA* 93, 7644-7648.
- Horwood N.J., Elliott J., Martin T.J. and Gillespie M.T. (2001). Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. *Endocrinology* 139, 4743-4746.
- Haynes D.R., Barg E., Crotti T.N., Holding C., Weedon H., Atkins G.J., Zannettino A., Ahern M.J., Coleman M., Roberts-Thomson P.J., Kraan M., Tak P.P. and Smith M.D. (2003). Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. *Rheumatology* 42, 123-134.
- Hofbauer L.C., Khosla S., Dunstan C., Lacey D.L., Boyle W. and Riggs B.L. (2000). The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. *J. Bone Min. Res.* 15, 2-12.
- Hofbauer L.C., Lacey D.L., Dunstan C.R., Spelsberg T.C., Riggs B.L. and Khosla S. (1999). Interleukin-1 β and tumor necrosis factor- α , but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. *Bone* 25, 255-259.
- Hollberg K., Hulthenby K., Hayman A., Cox T. and Andersson G. (2002). Osteoclasts from mice deficient in tartrate-resistant acid phosphatase have altered ruffled borders and disturbed intracellular vesicular transport. *Exp. Cell Res.* 279, 227-238.
- Hughes A.E., Ralston S.H. and Marken J. (2000). Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. *Nature Genet.* 24, 45-48.
- Hunter S.J., Rosen C.J. and Gay C.V. (1991). In vitro resorptive activity of isolated chick osteoclasts: Effects of carbonic anhydrase inhibition. *J. Bone Miner. Res.* 6, 61-66.
- Iotsova V., Caamano J., Loy J., Yang Y., Lewin A. and Bravo R. (1997). Osteopetrosis in mice lacking NF- κ B1 and NF- κ B2. *Nature Med.* 3, 1285-1289.
- Jimi E., Nakamura I., Amano H., Taguchi Y., Tsurukai T., Tamura M., Takahashi N. and Suda T. (1996). Osteoclast function is activated by osteoblastic cells through a mechanism involving cell-to-cell contact. *Endocrinology* 137, 2187-2190.
- Kartsogiannis V., Zhou H., Horwood N.J., Thomas R.J., Hards D.K., Quinn J.M., Niforas P., Ng K.W., Martin T.J. and Gillespie M.T. (1999). Localization of RANKL (receptor activator of NF- κ B ligand) mRNA and protein in skeletal and extraskeletal tissues. *Bone* 25, 525-534.
- Kim H.H., Lee D.E., Shin J.N., Lee Y.S., Jeon Y.M., Chung C.H., Ni J., Kwon B.S. and Lee Z.H. (1999). Receptor activator of NF- κ B recruits multiple TRAF family adaptors and activates c-Jun N-terminal kinase. *FEBS Lett.* 443, 297-302.
- Kitazawa R., Kitazawa S. and Maeda S. (1999). Promoter structure of mouse RANKL/ TRANCE/ OPG/ ODF gene. *Biochim. Biophys. Acta* 1445, 134-141.
- Kobayashi K., Takahashi N., Jimi E., Udagawa N., Takami M., Kotake S., Nakagawa N., Kinoshita M., Yamaguchi K. and Shima N. (2000). TNF- α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. *J. Exp. Med.* 191, 275-286.
- Kong Y.Y., Yoshida H., Sarosi I., Tan H.L., Timms E., Capparelli C., Morony S., Oliveira-dos-Santos A.J., Van G., Itie A., Khoo W., Wakeham A., Dunstan C.R., Lacey D.L., Mak T.W., Boyle W.J. and Penninger J.M. (1999). OPG is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. *Nature* 397, 315-323.
- Kornak U., Bosl M.R. and Kubisch C. (1999). Complete genomic structure of the CLCN6 and CLCN7 putative chloride channel genes. *Biochim. Biophys. Acta.* 1447, 100-106.
- Kornak U., Kasper D., Bosl M.R., Kaiser E., Schweizer M., Schulz A., Friedrich W., Delling G. and Jentsch T.J. (2001). Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. *Cell* 104, 205-215.
- Koseki T., Gao Y., Okahashi N., Murase Y., Tsujisawa T., Sato T., Yamato K. and Nishihara T. (2002). Role of TGF- β family in osteoclastogenesis induced by RANKL. *Cell Signal.* 14, 31-36.
- Kurihara N., Chenu C., Miller M., Civin C. and Roodman G.D. (1990). Identification of committed mononuclear precursors for osteoclast-like cells formed in long term human marrow cultures. *Endocrinology* 126, 2733-2741.
- Kudo O., Fujikawa Y., Itonaga I., Sabokbar A., Torisu T. and Athanasou N.A. (2002). Proinflammatory cytokine (TNF α) induction of human osteoclast formation. *J. Pathol.* 198,220-227.
- Kudo O., Sabokbar A., Pocock A., Itonaga I., Fujikawa Y. and Athanasou N.A. (2003). Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. *Bone* 32, 1-7.
- Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hsu H., Sullivan J., Hawkins N., Davy E., Capparelli C., Eli A., Qian Y.X, Kaufman S., Sarosi I., Shalhoub V., Senaldi G., Guo J., Delaney J and Boyle W.J. (1998). Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. *Cell* 93, 165-176.
- Lam J., Takeshita S., Barker J.E., Kanagawa O., Ross F.P. and Teitelbau S.L. (2000). TNF α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. *J. Clin. Invest.* 106, 1481-1488.
- Langdahl B.L., Carstens M., Stenkjaer L. and Eriksen E.F. (2002). Polymorphisms in the osteoprotegerin gene are associated with osteoporotic fractures. *J. Bone Miner. Res.* 17, 1245-1255.
- Li X., Pilbeam C.C., Pan L., Breyer R.M. and Raisz L.G. (2002). Effects of prostaglandin E2 on gene expression in primary osteoblastic cells from prostaglandin receptor knockout mice. *Bone* 30, 567-573.
- Li Y.P., Chen W., Liang Y., Li E. and Stashenko P. (1999). Atp6i-deficient mice exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular acidification. *Nat. Genet.* 23, 447-451.
- Lindberg M.K., Erlandsson M., Alatalo S.L., Windahl S., Andersson G., Halleen J.M., Carlsten H., Gustafsson J.A. and Ohlsson C. (2001). Estrogen receptor- α , but not estrogen receptor- β , is involved in the regulation of the OPG/RANKL (osteoprotegerin/receptor activator of NF- κ B ligand) ratio and serum interleukin-6 in male mice. *J. Endocrinol.* 171, 425-433.
- Liu F., Hata A., Baker J., Doody J., Carcamo J., Harland R.M. and Massague J. (1996). A human Mad protein acting as a BMP-regulated transcriptional activator. *Nature* 381, 620-623.
- Lomaga M.A., Yeh W.C., Sarosi I., Duncan G.S., Furlonger C., Ho A., Morony S., Capparelli C., Van G. and Kaufman S. (1999). TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. *Genes Dev.* 13, 1015-1024.
- Lopez-Rovira T., Chalaux E., Rosa J.L., Bartrons R. and Ventura F. (2000). Interaction and functional cooperation of NF- κ B with Smads. *J. Biol. Chem.* 275, 28937-28946.

- Lubberts E., Van Den Bersselaar L., Oppers-Walgreen B., Schwarzenberger P., Coenen-De Roo C.J., Kolls J.K., Joosten L.A. and Van Den Berg W.B. (2003). IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of receptor activator of NF- κ B ligand/osteoprotegerin balance. *J. Immunol.* 170, 2655-2662.
- Madyastha P.R., Yang S., Ries W.L. and Key L.L. Jr. (2000). IFN- γ enhances osteoclast generation in cultures of peripheral blood from osteopetrotic patients and normalizes superoxide production. *J. Interferon Cytokine Res.* 20, 645-652.
- Marie P.J., Hott M., Launay J.M., Graulet A.M. and Gueris J. (1993). In vitro production of cytokines by bone surface-derived osteoblastic cells in normal and osteoporotic postmenopausal women: relationship with cell proliferation. *J. Clin. Endocrinol. Metab.* 77, 824-830.
- Mercurio F. and Manning A.M. (1999). Multiple signals converging on NF- κ B. *Curr. Opin Cell Biol.* 11, 226-232.
- Michigami T., Kageyama T., Satomura K., Shima M., Yamaoka K., Nakayama M. and Ozono K. (2002). Novel mutations in the α 3 subunit of vacuolar H⁺-adenosine triphosphatase in a Japanese patient with infantile malignant osteopetrosis. *Bone* 30, 436-439.
- Miyazono K., Kusanagi K. and Inoue H. (2001). Divergence and Convergence of TGF- β /BMP Signaling. *J. Cell Physiol.* 18, 265-276.
- Mizuno A., Amizuka N., Irie K., Murakami A., Fujise N., Kanno T., Sato Y., Nakagawa N., Yasuda H., Mochizuki S., Gomibuchi T., Yano K., Shima N., Washida N., Tsuda E., Morinaga T., Higashio K. and Ozawa H. (1998). Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. *Biochem. Biophys. Res. Commun.* 247, 610-615.
- Murakami T., Yamamoto M., Ono K., Nishikawa M., Nagata N., Motoyoshi K. and Akatsu T. (1998). Transforming growth factor- β 1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells. *Biochem. Biophys. Res. Commun.* 252, 747-752.
- Nakashima T., Kobayashi Y., Yamasaki S., Kawakami A., Eguchi K., Sasaki H. and Sakai H. (2000). Protein expression and functional difference of membrane-bound and soluble receptor activator of NF- κ B ligand: modulation of the expression by osteotropic factors and cytokines. *Biochem. Biophys. Res. Commun.* 275, 768-775.
- Neeck G., Renkawitz R. and Eggert M. (2002). Molecular aspects of glucocorticoid hormone action in rheumatoid arthritis. *Cytokines Cell. Mol. Ther.* 7, 61-69.
- Nesbitt S.A. and Horton M.A. (1997). Trafficking of matrix collagens through bone-resorbing osteoclasts. *Science* 27, 266-269.
- Onyia J.E., Libermann T.A., Bidwell J., Arnold D., Tu Y., McClelland P. and Hock J.M. (1997). Parathyroid hormone (1-34)-mediated interleukin-6 induction. *J. Cell Biochem.* 67, 265-274.
- Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., Moorman M.A., Simonetti D.W., Craig S. and Marshak D.R. (1999). Multilineage potential of adult human mesenchymal stem cells. *Science* 284, 143-147.
- Quinn J.M., Itoh K., Udagawa N., Hausler K., Yasuda H., Shima N., Mizuno A., Higashio K., Takahashi N., Suda T., Martin T.J. and Gillespie M.T. (2001). Transforming growth factor β affects osteoclast differentiation via direct and indirect actions. *J. Bone Miner. Res.* 16, 1787-1794.
- Redlich K., Hayer S., Maier A., Dunstan C.R., Tohidast-Akrad M., Lang S., Turk B., Pietschmann P., Woloszczuk W., Haralambous S., Kollias G., Steiner G., Smolen J.S. and Schett G. (2002). Tumor necrosis factor α -mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. *Arthritis Rheum.* 46, 785-792.
- Ridderstad A., Abedi-Valugerdi M. and Moller E. (1991). Cytokines in rheumatoid arthritis. *Ann. Med.* 23, 219-223.
- Romas E., Sims N.A., Hards D.K., Lindsay M., Quinn J.W., Ryan P.F., Dunstan C.R., Martin T.J. and Gillespie M.T. (2002). Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. *Am. J. Pathol.* 161, 1419-1427.
- Ross F.P., Chappel J., Alvarez J.I., Sander D., Butler W.T., Farach-Carson M.C., Mintz K.A., Robey P.G., Teitelbaum S.L. and Cheres D.A. (1993). Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin α v β 3 potentiate bone resorption. *J. Biol. Chem.* 268, 9901-9907.
- Roux S., Pichaud F., Quinn J., Lalande A., Morieux C., Jullienne A and de Vernejoul M.C. (1997). Effects of prostaglandins on human hematopoietic osteoclast precursors. *Endocrinology* 138, 1476-1482.
- Sabokbar A., Kudo O. and Athanasou N.A. (2003). Two distinct cellular mechanisms of osteoclast formation and bone resorption in periprosthetic osteolysis. *J. Orthop. Res.* 21, 73-80.
- Saika M., Inoue D., Kido S. and Matsumoto T. (2001). 17 β -estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor- α . *Endocrinology* 142, 2205-2212.
- Salo J., Lehenkari P., Metsikko K. and Vananenen H.K. (1997). Removal of osteoclast bone resorption products by transcytosis. *Science* 276, 270-273.
- Sasaki N., Kusano E., Ando Y., Yano K., Tsuda E. and Asano Y. (2001). Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis. *Nephrol. Dial. Transplant.* 16, 479-782.
- Schlesinger P.H., Blair H.C., Teitelbaum S.L. and Edwards J.C. (1997). Characterization of the osteoclast ruffled border chloride channel and its role in bone resorption. *J. Biol. Chem.* 272, 18636-18643.
- Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., Nguyen H.Q., Wooden S., Bennett L., Boone T., Shimamoto G., DeRose M., Elliott R., Colombero A., Tan H.L., Trail G., Sullivan J., Davy E., Bucay N., Renshaw-Gegg L., Hughes T.M., Hill D., Pattison W., Campbell P. and Boyle W.J. (1997). Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. *Cell* 89, 309-319.
- Smith A.N., Skaug J., Choate K.A., Nayir A., Bakkaloglu A., Ozen S., Hulton S.A., Sanjad S.A., Al-Sabban E.A., Lifton R.P., Scherer S.W. and Karet F.E. (2000). Mutations in ATP6N1B, encoding a new kidney vacuolar proton pump 116-kD subunit, cause recessive distal renal tubular acidosis with preserved hearing. *Nature Genet.* 26, 71-75.
- Smith A.N., Finberg K.E., Wagner C.A., Lifton R.P., Devonald M.A., Su Y. and Karet F.E. (2001). Molecular cloning and characterization of Atp6n1b: a novel fourth murine vacuolar H⁺-ATPase α -subunit gene. *J. Biol. Chem.* 276, 2382-42388.
- Soriano P., Montgomery C., Geske R and Bradley A. (1991). Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. *Cell* 64, 693-702.
- Srivastava S., Toraldo G., Weitzmann M.N., Cenci S., Ross F.P. and Pacifici R. (2001). Estrogen decreases osteoclast formation by down-regulating receptor activator of NF- κ B ligand (RANKL)-induced JNK activation. *J. Biol. Chem.* 276, 8836-8840.
- Suda T., Udagawa N., Nakamura J., Miyaura C. and Takahashi N.

Osteoclast pathology

- (1995). Modulation of osteoclast differentiation by local factors. *Bone* 17, (Suppl 2) 87S-91S.
- Suda T., Ueno Y., Fujii K. and Shinki T. (2003). Vitamin D and bone. *J Cell Biochem.* 88, 259-266.
- Takahashi N., Idagawa N., Tamaka S., Murakami H., Owan I., Tamura I. and Suda T. (1994). Postmitotic osteoclast precursors are mononuclear cells which express macrophage-associated phenotypes. *Devel. Biol.* 163, 212-221.
- Tani-Ishii N., Tsunoda A., Teranaka T. and Umemoto T. (1999). Autocrine regulation of osteoclast formation and bone resorption by IL-1 α and TNF α . *J. Dental Res.* 78, 1617-1623.
- Tanaka S., Takahashi N., Udagawa N., Tamura T., Akatsu T., Stanly E.R., Kurokawa T. and Suda T. (1993). Macrophage colony stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. *J. Clin. Invest.* 91, 257-265.
- Tanaka S., Amling M., Neff L., Peyman A., Uhlmann E., Levy J.B. and Baron R. (1996). c-Cbl is downstream of c-Src in a signalling pathway necessary for bone resorption. *Nature* 383, 528-531.
- Taylor P.C. (2003). Anti-TNF α therapy for rheumatoid arthritis: an update. *Intern Med.* 42, 15-20.
- Teti A., Blair H.C., Teitelbaum S.L., Kahn A.J., Koziol C.M., Konsek J, Zamboni-Zallone A. and Schlesinger P.H. (1989). Cytoplasmic pH regulation and chloride/bicarbonate exchange in avian osteoclasts. *J. Clin Invest.* 83, 227-233.
- Tezuka K., Tezuka Y., Maejima A., Sato T., Nemoto K., Kamioka H., Hakeda Y. and Kumegawa M. (1994). Molecular cloning of a possible cysteine proteinase predominantly expressed in osteoclasts. *J. Biol. Chem.* 269, 1106-1109.
- Thirunavukkarasu K., Miles R.R., Halladay D.L., Yang X., Galvin R.J., Chandrasekhar S., Martin T.J. and Onyia J.E. (2001). Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor- β (TGF- β). Mapping of the OPG promoter region that mediates TGF- β effects. *J. Biol. Chem.* 276, 36241-36250.
- Tondravi M.M., McKercher S.R., Anderson K., Erdmann J.M., Quiroz M., Maki R. and Teitelbaum S.L. (1997). Osteopetrosis in mice lacking haematopoietic transcription factor PU.1. *Nature* 385, 81-84.
- Toraldo G., Roggia C., Qian W.P., Pacifici R. and Weitzmann M.N. (2003). IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor- κ B ligand and tumor necrosis factor- α from T cells. *Proc. Natl. Acad. Sci. USA* 100, 125-130.
- Tsuda E., Goto M., Mochizuki S., Yano K., Kobayashi F., Morinaga T. and Higashio K. (1997). Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. *Biochem. Biophys. Res. Commun.* 234, 137-142.
- Walker D.G. (1973). Osteopetrosis cured by temporary parabiosis. *Science* 180, 875.
- Walker D.G. (1975). Bone resorption restored in osteopetrotic mice by transplants of normal bone marrow and spleen cells. *Science* 190, 784-785.
- Whyte M.P., Obrecht S.E., Finnegan P.M., Jones J.L., Podgornik M.N., McAlister W.H. and Mumm S. (2002). Osteoprotegerin deficiency and juvenile Paget's disease. *N. Engl. J. Med.* 347, 175-184.
- Wong B.R., Rho J., Arron J., Robinson E., Orlinick J., Chao M., Kalachikov S., Cayani E., Bartlett F.S., Frankel W.N., Lee S.Y. and Choi Y. (1997). TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. *J. Biol. Chem.* 272, 25190-25194.
- Wong B.R., Besser D., Kim N., Arron J.R., Vologodskaja M., Hanafusa H. and Choi Y. (1999). TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. *Mol. Cell.* 4, 1041-1049.
- Wuyts W., Van Wesenbeeck L., Morales-Piga A., Ralston S., Hocking L., Vanhoenacker F., Westhovens R., Verbruggen L., Anderson D., Hughes A. and Van Hul W. (2001). Evaluation of the role of RANK and OPG genes in Paget's disease of bone. *Bone* 28, 104-107.
- Yang S., Ries W.L. and Key L.L. Jr. (1999). Superoxide generation in transformed B-lymphocytes from patients with severe, malignant osteopetrosis. *Mol Cell Biochem.* 199, 15-24.
- Yanagisawa J., Yanagi Y., Masuhiro Y., Suzawa M., Watanabe M., Kashiwagi K., Toriyabe T., Kawabata M., Miyazono K. and Kato S. (1999). Convergence of transforming growth factor- β and vitamin D signaling pathways on SMAD transcriptional coactivators. *Science* 283, 1317-1321.
- Yano K., Tsuda E., Washida N., Kobayashi F., Goto M., Harada A., Ikeda K., Higashio K. and Yamada Y. (1999). Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. *J. Bone Miner. Res.* 14, 518-527.
- Yoshida H., Hayashi S., Kunisada T., Ogawa M., Nishikawa S., Okamura H., Sudo T., Shultz L.D. and Nishikawa S. (1990). The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. *Nature* 345, 442-444.
- Yasuda H., Shima N., Nakagawa N., Mochizuki S.I., Yano K., Fujise N., Sato Y., Goto M., Yamaguchi K., Kuriyama M., Kanno T., Murakami A., Tsuda E., Morinaga T. and Higashio K. (1998). Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. *Endocrinology* 139, 1329-1337.
- Zhang X., Schwarz E.M., Young D.A., Puzas J.E., Rosier R.N. and O'Keefe R.J. (2002). Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. *J. Clin. Invest.* 109, 1405-1415.
- Ziolkowska M., Kurowska M., Radzikowska A., Luszczkiewicz G., Wiland P., Dziewczopolski W., Filipowicz-Sosnowska A., Pazdur J., Szechinski J., Kowalczewski J., Rell-Bakalarska M. and Maslinski W. (2002). High levels of osteoprotegerin and soluble receptor activator of nuclear factor κ B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor a treatment. *Arthritis Rheum.* 46, 1744-1753.